醒脑静辅助卡马西平治疗脑卒中后继发性癫痫疗效观察

Clinical observation of the therapeutic effect of Xingnaojing combined with carbamazepine on epilepsy secondary to stroke

目的探讨醒脑静辅助卡马西平治疗脑卒中后继发性癫痫临床疗效。方法将100例脑卒中后继发性癫痫患者随机分为对照组与观察组,对照组给予抗癫痫药物卡马西平进行治疗,观察组在此基础上给予醒脑静注射液治疗。比较2组临床疗效、痫样放电及累及导联数、不同类型癫痫临床疗效、不良反应发生情况。结果观察组临床治疗有效率(92.00%)明显高于对照组;痫样放电(6.92±1.34)t/180s,累及导联数2.98±0.56,不良反应发生率(10%)明显低于对照组;醒脑静辅助卡马西平治疗SPS、CPS、GS及不能分类癫痫临床总有效率分别为95.45%、90.00%、90.00%及87.50%。结论醒脑静辅助卡马西平治疗脑卒中后继发性癫痫临床疗效显著,安全性高,值得在临床推广应用。

Objective To investigate the clinical efficacy of Xingnaojing assisted carbamazepine on epilepsy secondary to stroke. Methods 100 cases of patients with secondary epilepsy after stroke were randomly divided into control group and ob-servation group. The control group was given antiepileptic drug carbamazepine for treatment ,and the observation group was given xingnaojing on basis of the control group. The number of leads involved in epileptic discharges ,the clinical efficacy of dif-ferent types of epilepsy and adverse events of the two groups were compared.Results The clinical efficacy of the observation group （92.00% ） was significantly higher than that of the control group ;epileptic discharges （6.92 ± 1.34） t /180s ,involved lead number （2.98 ± 0.56） ,adverse reactions （10% ） were all significantly lower than those of the control group ;the clinically total effective rate of Xingnaojing assisted carbamazepine treated SPS ,CPS ,GS and such epilepsy which couldn’t be classified were 95.45% ,90.00% ,90.00% and 95.45% respectively. Conclusion The clinical efficacy of Xingnaojing assisted carbam-azepine on epilepsy secondary to stroke is significantly obvious ,its safety is better ,and deserve to be promoted in clinical appli-cation.